Featured

LNP mRNA delivery gets a metabolic boost from amino acid supplement

Notice: The article we intended to feature this week was briefly delayed in publication. We will share it with you as soon as the embargo is lifted....

Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy

Using a bilateral, humanized OX40 MC38 tumor model, Liu and Zhao et al. demonstrated that OX40 agonist Ab (agOX40) therapy increased infiltration of NOS2+ pro-inflammatory macrophages and effector CD8...

Macrophages restrict tumor immune infiltration by controlling collagen topography

Using tissue imaging, transcriptional analysis, and machine learning, Fusilier et al. found that immune cell infiltration and localization within established fibrotic tumors could be predicted by the ...

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

To improve the potency of a prostate TAA-specific TCR, Chen and Mao et al. screened for CDR hotspot mutations that could increase catch-bond formation and thus TCR sensitivity, without modifying TCR a...

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice

Zhang, Gao, and Hu et al. addressed ways to enhance DC–T cell crosstalk in the TIME. BiDT, a bispecific DC–T cell engager (anti-Tim3–IFNα fusion), simultaneously bound Tim3 on exhausted TILs and activ...

See all for this week

Previous Digests

LNP mRNA delivery gets a metabolic boost from amino acid supplement

March 25, 2026

Lipid nanoparticles (LNPs) have allowed for the delivery of therapeutic mRNA for various therapeutic applications. However, in vivo delivery efficacy is often limited, and research is focused on optimization of LNP formulations. In recent work published in Science Translational...

The surprising effect of TOX in CD4+ T cells

March 18, 2026

In settings of chronic antigen stimulation, such as chronic infection and cancer, expression of the transcription factor TOX in CD8+ T cells has been associated with cell persistence and survival, but also with exhaustion, dysfunction, and poor prognosis. As...

Neoantigen vaccination boosts long-lasting T cell responses in TNBC

March 11, 2026

Triple-negative breast cancer (TNBC) is characterized by DNA repair deficiency, genomic instability, and an immunogenic tumor microenvironment, suggesting it might serve as a candidate for individualized vaccination targeting somatic tumor mutation-associated neoantigens. Sahin, Schmidt, et al. recently published the...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials